Macropa-4-(4-(3-butylthioureido)phenethoxy)picolinic
Macropa-4-(4-(3-butylthioureido)phenethoxy)picolinic is a biochemical assay reagent that can be used for synthesis of Ac-macropa (HY-163608). Ac-macropa is a PSMA-targeted Actinium-225 Conjugate, and can be used for study of prostate cancer.
For research use only. We do not sell to patients.
- Formula: C39H54N6O9S
- Molecular Weight:782.95
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Macropa-4-(4-(3-butylthioureido)phenethoxy)picolinic can be labled with Actinium-225 to synthesis PSMA-Targeted Actinium-225 Conjugate[1].
PSMA-Targeted Actinium-225 Conjugate exhibits potent, dose-dependent cytotoxicity in PSMA-expressing C4-2, LNCaP, MDA-PCa-2b, and 22Rv1 prostate cancer cells, but not in PSMA-negative PC-3 and DU-145 prostate cancer cells[1].
PSMA-Targeted Actinium-225 Conjugate induces G2/M cell cycle arrest, dose-dependent reactive oxygen species formation, and DNA damage in PSMA-expressing C4-2, LNCaP, and 22Rv1 prostate cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Chemical Information
-
Molecular Weight 782.95
-
Formula C39H54N6O9S
-
SMILES
S=C(NC1=CC=C(CCOC2=CC(C([OH])=O)=[N]C(C[N]3CC[O]CC[O]CC[N](CC[O]CC[O]CC3)CC4=CC=CC(C([OH])=O)=[N]4)=C2)C=C1)NCCCC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Schatz CA, et al. Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer. Clin Cancer Res. 2024 Jun 3;30(11):2531-2544. [Content Brief]
[2]. Hope TA, et al. PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. Lancet. 2021 Feb 27;397(10276):768-769. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Macropa-4-(4-(3-butylthioureido)phenethoxy)picolinic Related Classifications
HY-186220 Related Classifications
Powered by Bioz